Harmony Biosciences Holdings (HRMY) EBIT Margin (2020 - 2026)
Harmony Biosciences Holdings (HRMY) posted EBIT Margin of 17.31% for Q1 2026, up 9.46% sequentially from 15.82% in Q4 2025, and down 1313.0% YoY from 1.43% in Q1 2025.
Harmony Biosciences Holdings (HRMY) EBIT Margin (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported EBIT Margin for 7 years, with the latest figure at 17.31% in Q1 2026.
- Quarterly EBIT Margin fell 1313.0% year-over-year to 17.31% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.08% (down 511.0% YoY) and the FY2025 annual result came in at 24.0%, down 269.0% from the prior year.
- EBIT Margin rose to 17.31% in Q1 2026 per HRMY's latest filing, from 15.82% in the prior quarter.
- Over five years, EBIT Margin peaked at 40.25% in Q3 2023 and troughed at 10.15% in Q3 2022.
- A 5-year average of 27.37% and a median of 30.45% in 2025 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2023 and 2024: EBIT Margin surged 3010 bps in 2023, then tumbled 2259 bps in 2024.
- Over 5 years, EBIT Margin stood at 37.11% in 2022, then sank by 36 bps to 23.87% in 2023, then grew by 16 bps to 27.69% in 2024, then slumped by 43 bps to 15.82% in 2025, then rose by 9 bps to 17.31% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 17.31%, 15.82%, and 27.35% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 34.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 34.18% |
| Mar 31, 2026 | 17.31% |
| Dec 31, 2025 | 15.82% |
| Sep 30, 2025 | 27.35% |
| Jun 30, 2025 | 24.03% |
| Mar 31, 2025 | 30.45% |
| Dec 31, 2024 | 27.69% |
| Sep 30, 2024 | 33.17% |
| Jun 30, 2024 | 12.36% |
| Mar 31, 2024 | 33.65% |
| Dec 31, 2023 | 23.87% |
| Sep 30, 2023 | 40.25% |
| Jun 30, 2023 | 34.95% |
| Mar 31, 2023 | 33.93% |
| Dec 31, 2022 | 37.11% |
| Sep 30, 2022 | 10.15% |
| Jun 30, 2022 | 30.94% |
| Mar 31, 2022 | 32.30% |
| Dec 31, 2021 | 31.39% |
| Sep 30, 2021 | 26.08% |